A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
| Status: | Completed |
|---|---|
| Conditions: | Peripheral Vascular Disease, Neurology, Neurology, Neurology, Neurology, Neurology, Ocular |
| Therapuetic Areas: | Cardiology / Vascular Diseases, Neurology, Ophthalmology |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 10/14/2017 |
| Start Date: | July 2013 |
| End Date: | December 2015 |
Dalfampridine Treatment for Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)
Determine whether dalfampridine (Ampyra) can improve visual function in patients who have had
nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
nonarteritic ischemic optic neuropathy (NAION) with stable visual impairment.
The aim of this study is to determine whether dalfampridine can improve visual function in
patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual
impairment.
The objective of this double masked crossover study is to determine whether visual function
can be improved in numerous parameters. This includes high contrast visual acuity, low
contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology,
multi focal electro retinography (mERG), visual evoked potential (VEP), and structure,
spectral domain optical coherence tomography (OCT).
Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in
stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic
ischemic optic neuropathy (NAION) will have improved visual function with the administration
of dalfampridine.
patients who have had nonarteritic ischemic optic neuropathy (NAION) with stable visual
impairment.
The objective of this double masked crossover study is to determine whether visual function
can be improved in numerous parameters. This includes high contrast visual acuity, low
contrast visual acuity, visual field, visual quality of life (VFQ-39), electrophysiology,
multi focal electro retinography (mERG), visual evoked potential (VEP), and structure,
spectral domain optical coherence tomography (OCT).
Based on the promising results of the use of dalfampridine in Multiple Sclerosis (MS) and in
stroke, we hypothesize that the patients with chronic stable deficits after nonarteritic
ischemic optic neuropathy (NAION) will have improved visual function with the administration
of dalfampridine.
Inclusion Criteria:
- NAION 6 months prior to enrollment
- visual acuity of 20/40 or worse
Exclusion Criteria:
Current use of Dalfampridine (Ampyra)
- Pregnancy
- History of seizures
- Renal Failure
- Not able to perform testing
We found this trial at
1
site
Click here to add this to my saved trials
